Higher TYROBP and lower SOX6 as predictive biomarkers for poor prognosis of clear cell renal cell carcinoma: A pilot study

Abstract

Background: Clear cell renal carcinoma (ccRCC) is the most common subtype of renal cancer, accounting for approximately 75% of all histological types of renal cancer, and is the leading cause of death from renal cancer. However, the molecular mechanism of tyrosine kinase binding protein (TYROBP) and sex-determining region Y Box-6 (SOX6) in the ccRCC was not precise. Methods: Bioinformatics analysis was performed to explore the hub role of TYROBP and SOX6 on the ccRCC. A total of 6 patients with clear cell renal cell carcinoma (ccRCC) were recruited. HE staining was performed to observe the pathology result of ccRCC. Immunohistochemistry and Immunofluorescence assay was made to detect the protein expression of TYROBP. Total RNA was extracted using TRIzol to examine the mRNA expression of TYROBP via the Real time quantitative polymerase chain reaction. The strong correlation between the expression of TYROBP and the survival time of ccRCC patients was performed by the BP neural network and support vector machine. Results: Compared with the control group, the expression of SOX6 was downregulated in the samples with ccRCC. However, the expression of TYROBP was higher in the samples with ccRCC than in the control group. Compared with the patients with high SOX6 expression, the patients with low SOX6 expression have a poor survival prognosis (HR=0.39, P < .05). However, the patients with high TYROBP expression have a shorter survival time than the patients with low TYROBP expression (HR=1.66, P < .05). The genes related with TYROBP and SOX6 are mainly enriched in the regulation of cell activation, leukocyte activation, negative regulation of cell activation, myeloid leukocyte activation, positive regulation of response to external stimulus, immune response-regulating signaling pathway. The interaction between TYROBP, SOX6, and kidney neoplasms was drawn, and the inference score of TYROBP and SOX6 on the kidney neoplasms was high. Conclusion: In conclusion, TYROBP is highly expressed in renal clear cell carcinoma, and when this molecule is highly expressed, the survival prognosis of renal carcinoma is poor. TYROBP and SOX6 may be potential targets for diagnosing and treating renal clear cell carcinoma.

Deciphering the molecular and clinical characteristics of TREM2, HCST, and TYROBP in cancer immunity: A comprehensive pan-cancer study

“…Consistent with previous research, TREM2, HCST, and TYROBP were highly expressed in ESCA, GBM, HNSC, KIRC, KIRP [ [22] , [23] , [24] , [25] , [26] , [27] ], and expressed at low levels in LUAD and LUSC. Studies have shown that their activation can mediate NK cell killing activity in lung cancer, which typically has reduced NK cell levels, possibly contributing to their low expression [ 28 , 29 ]; In BLCA and COAD, TREM2 is highly expressed [ 30 , 31 ], while HCST and TYROBP display opposite trends, potentially due to tumor heterogeneity, competitive binding of HCST and TYROBP to other receptors, or other factors that warrant further investigation.…”

TYROBP as a molecular target in cholangiocarcinoma, renal cancer and abdominal aortic aneurysm

“…[ 30 , 31 ] There are studies suggesting an interaction between TYROBP, Sox6 and renal tumors, with higher inferred scores for TYROBP and Sox6 for renal tumors. [ 32 ] The high expression of TYROBP is closely related to the poor prognosis and immune cell infiltration of clear cell renal cell carcinoma. [ 33 ] It has also been shown that in vivo experiments revealed that TYROBP is significantly underexpressed in AAA abdominal aortic tissue.…”

Mining and exploration of appendicitis nursing targets: An observational study

“…TYROBP-related signaling pathways can continuously activate immune cells, maintaining and exacerbating the inflammatory response and delaying the healing process. [31] After TYROBP protein binds to its ligand, it can activate multiple signaling pathways such as MAPK, NF-κB, which play important roles in the inflammatory process. TYROBP may participate in inflammation regulation by modulating these signaling pathways.…”